According to Zacks, “Sangamo BioSciences, Inc. is a leader in the development of novel transcription factors for the regulation of gene expression. Transcription factors are proteins that turn genes on or off by recognizing specific DNA sequences. The Universal Gene Recognition technology platform enables the engineering of a class of transcription factors known as zinc finger DNA binding proteins. “
Other research analysts have also recently issued research reports about the company. Jefferies Group reissued a buy rating on shares of Sangamo BioSciences in a research note on Friday, August 5th. Cowen and Company reissued a buy rating on shares of Sangamo BioSciences in a research note on Wednesday, August 10th. Finally, Janney Montgomery Scott cut Sangamo BioSciences from a buy rating to a neutral rating and decreased their price target for the stock from $15.00 to $8.00 in a research note on Thursday, August 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $15.30.
Sangamo BioSciences (NASDAQ:SGMO) opened at 4.60 on Wednesday. Sangamo BioSciences has a 52 week low of $4.08 and a 52 week high of $9.91. The firm’s market cap is $324.84 million. The company has a 50-day moving average of $4.55 and a 200 day moving average of $5.68.
Sangamo BioSciences (NASDAQ:SGMO) last released its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by $0.14. Sangamo BioSciences had a negative return on equity of 36.08% and a negative net margin of 261.81%. The business earned $3.70 million during the quarter, compared to the consensus estimate of $5.38 million. During the same period in the previous year, the company posted ($0.17) EPS. The company’s revenue for the quarter was down 56.0% compared to the same quarter last year. On average, equities analysts predict that Sangamo BioSciences will post ($1.11) earnings per share for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Adage Capital Partners GP L.L.C. boosted its position in shares of Sangamo BioSciences by 105.6% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,850,000 shares of the biopharmaceutical company’s stock valued at $11,193,000 after buying an additional 950,000 shares in the last quarter. Numeric Investors LLC boosted its position in shares of Sangamo BioSciences by 329.2% in the second quarter. Numeric Investors LLC now owns 465,523 shares of the biopharmaceutical company’s stock valued at $2,695,000 after buying an additional 357,054 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Sangamo BioSciences by 140.7% in the first quarter. Renaissance Technologies LLC now owns 504,064 shares of the biopharmaceutical company’s stock valued at $3,050,000 after buying an additional 294,664 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Sangamo BioSciences by 9.5% in the second quarter. Vanguard Group Inc. now owns 2,694,393 shares of the biopharmaceutical company’s stock valued at $15,601,000 after buying an additional 234,286 shares in the last quarter. Finally, Prudential Financial Inc. purchased a new position in shares of Sangamo BioSciences during the first quarter valued at $1,384,000. 65.24% of the stock is owned by institutional investors and hedge funds.
About Sangamo BioSciences
Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.